Intralesional T-VEC and combinations for melanoma

Share :
Published: 18 May 2017
Views: 3102
Prof Sanjiv Agarwala - St. Luke's Cancer Center, Easton, USA

Prof Agarwala speaks with ecancer at EADO 2017 about intralesional therapies, including oncolytic talimogene laherparepvec (T-VEC), to treat melanoma.

He highlights the complementary roles of intralesional therapies with systemic therapies including immunotherapeutics, and that local injections can 'warm up' tumours, increasing immune penetration.

Prof Agarwala highlights upcoming trials in combination with pembrolizumab and ipilimumab, and his view of future combination or sequencing of combined treatments.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.